ONVO · Organovo Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q1 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.0K | $28.0K | $37.0K | - | $5.0K | $0 | $0 | $1.50M | - | - |
| Cost of Revenue | $0 | $0 | $0 | - | - | - | - | - | - | - |
| Gross Profit | $26.0K | $28.0K | $37.0K | - | - | - | - | - | - | - |
| R&D | $1.14M | $923.0K | $1.00M | - | $1.43M | $1.33M | $1.67M | $580.0K | $926.0K | $679.0K |
| SG&A | $1.64M | $1.74M | $1.95M | - | $2.25M | $2.78M | $2.60M | $1.98M | $2.57M | $2.83M |
| Total Operating Expenses | $2.78M | $2.66M | $2.95M | - | $3.49M | $3.43M | $3.24M | $2.56M | $3.50M | $3.51M |
| D&A | - | - | $61.0K | - | - | - | $67.0K | $25.0K | - | - |
| Operating Income | ($2.75M) | ($2.63M) | ($2.92M) | - | ($3.68M) | ($4.12M) | ($4.20M) | ($2.56M) | ($3.50M) | ($3.51M) |
| Interest Expense | $4.0K | $0 | $4.0K | - | - | - | - | - | - | - |
| Income Tax | $0 | $2.0K | $0 | - | $0 | $0 | $2.0K | $0 | $2.0K | $0 |
| Net Income | ($2.69M) | ($2.54M) | ($2.84M) | - | ($3.60M) | ($3.99M) | ($4.03M) | ($2.53M) | ($3.50M) | ($3.50M) |
| EPS - Basic | ($1.03) | ($0.98) | ($1.14) | - | ($0.40) | ($0.46) | ($0.46) | - | - | - |
| EPS - Diluted | ($1.03) | ($0.98) | ($1.14) | - | ($0.40) | ($0.46) | ($0.46) | - | - | - |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q1 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.29M | $6.68M | $9.05M | $2.90M | $5.29M | $7.62M | $10.75M | $28.68M | $30.27M | $33.79M |
| Accounts Receivable | $33.0K | $32.0K | $32.0K | $33.0K | $33.0K | $55.0K | $149.0K | - | - | - |
| Inventory | $0 | $640.0K | $0 | $297.0K | - | - | $0 | - | - | - |
| Accounts Payable | $671.0K | $580.0K | $673.0K | $627.0K | $471.0K | $435.0K | $488.0K | $415.0K | $605.0K | $958.0K |
| Current Assets | $6.04M | $7.59M | $9.68M | $3.94M | $6.24M | $8.30M | $11.70M | $29.53M | $31.17M | $34.30M |
| Total Assets | $6.96M | $9.69M | $11.98M | $6.35M | $8.88M | $11.16M | $14.76M | $33.30M | $35.09M | $35.88M |
| Current Liabilities | $2.48M | $2.45M | $2.14M | $1.86M | $1.70M | $1.60M | $1.77M | $1.38M | $2.01M | $1.68M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.52M | $2.62M | $2.44M | $2.75M | $2.70M | $2.71M | $2.98M | $3.09M | $3.80M | - |
| Stockholders' Equity | $4.44M | $7.07M | $9.54M | $3.60M | $6.18M | $8.46M | $11.78M | $30.21M | $31.29M | $34.21M |
| Retained Earnings | ($350.24M) | ($347.55M) | ($345.00M) | ($339.67M) | ($336.62M) | ($333.02M) | ($329.03M) | ($307.74M) | ($305.83M) | ($302.33M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q1 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($3.94M) | - | - | - | ($5.31M) | ($1.41M) | - | - |
| Investing Cash Flow | - | - | $0 | - | - | - | $764.0K | ($194.0K) | - | - |
| Financing Cash Flow | - | - | $1.68M | - | - | - | $0 | $251.0K | - | - |
| CapEx | - | - | $0 | - | - | - | $15.0K | $0 | - | - |
| Free Cash Flow | - | - | ($3.94M) | - | - | - | ($5.33M) | ($1.41M) | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q1 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 100.0% | 100.0% | 100.0% | - | - | - | - | - | - | - |
| Operating margin | -10576.9% | -9410.7% | -7878.4% | - | -73600.0% | - | - | -170.6% | - | - |
| EBITDA margin | - | - | -7713.5% | - | - | - | - | -168.9% | - | - |
| Net margin | -10350.0% | -9089.3% | -7683.8% | - | -72080.0% | - | - | -168.8% | - | - |
| Free cash flow margin | - | - | -10648.6% | - | - | - | - | -94.2% | - | - |
| FCF / Net income | - | - | 1.39 | - | - | - | 1.32 | 0.56 | - | - |
| R&D / Revenue | 4384.6% | 3296.4% | 2705.4% | - | 28680.0% | - | - | 38.7% | - | - |
| SG&A / Revenue | 6292.3% | 6214.3% | 5273.0% | - | 45020.0% | - | - | 131.9% | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -38.7% | -26.3% | -23.7% | - | -40.6% | -35.8% | -27.3% | -7.6% | -10.0% | -9.8% |
| Return on equity | -60.6% | -36.0% | -29.8% | - | -58.3% | -47.2% | -34.2% | -8.4% | -11.2% | -10.2% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.44 | 3.10 | 4.52 | 2.12 | 3.67 | 5.18 | 6.61 | 21.35 | 15.54 | 20.48 |
| Quick ratio | 2.44 | 2.84 | 4.52 | 1.96 | 3.67 | 5.18 | 6.61 | 21.35 | 15.54 | 20.48 |
| Cash ratio | 1.73 | 2.73 | 4.23 | 1.56 | 3.11 | 4.76 | 6.08 | 20.73 | 15.09 | 20.17 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -687.5x | - | -728.8x | - | - | - | - | - | - | - |
| Equity multiplier | 1.57 | 1.37 | 1.26 | 1.76 | 1.44 | 1.32 | 1.25 | 1.10 | 1.12 | 1.05 |
| Liabilities / Assets | 0.36 | 0.27 | 0.20 | 0.43 | 0.30 | 0.24 | 0.20 | 0.09 | 0.11 | - |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.05 | - | - |
| Inventory turnover | - | 0.00 | - | - | - | - | - | - | - | - |
| Days sales outstanding | 463d | 417d | 316d | - | 2409d | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | -100.0% | - | - | - |
| Revenue CAGR (3y) | - | - | -70.9% | - | -74.4% | - | - | 29.6% | - | - |
| Revenue CAGR (5y) | -38.6% | -53.1% | -43.9% | - | -66.3% | - | - | 11.0% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | -5.1% | -17.3% | -63.9% | 8.1% | -40.4% | 60.8% |
| Net income growth (YoY) | - | - | - | - | -3.0% | -14.0% | -59.1% | 8.6% | -39.4% | 60.8% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | -276.9% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | 164.9% | -69.4% | -80.2% | -75.3% | -61.0% | -22.9% | 50.8% | 71.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-03-31.
Product / service
$263.0K totalRoyalty$119.0K · 45.2%
Sales Based Royalties$119.0K · 45.2%
Product$25.0K · 9.5%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing ORGANOVO HOLDINGS against the 5 most active filers in the same SIC group.